Sector News

AstraZeneca oncology head jumps ship to become Innate CEO

December 20, 2016
Life sciences

AstraZeneca is losing its head of oncology, Mondher Mahjoubi, who is departing to lead French biotech company Innate Pharma.

Innate said on Monday that Mahjoubi would take over as chief executive on Dec. 30, replacing Herve Brailly who is moving on to become chairman of the supervisory board.

The loss of Mahjoubi is a setback for AstraZeneca, given the British drugmaker’s focus on new cancer treatments. Mahjoubi previously worked at Roche’s (ROG.S) Genentech unit before joining AstraZeneca, where he has helped lead oncology strategy.

His departure comes ahead of key clinical trial read-outs for the company’s experimental immunotherapy drugs.

AstraZeneca said Mahjoubi’s successor would be announced shortly.

For Mahjoubi, the move to Innate offers the opportunity to run a company that specialises in immuno-oncology, which is now transforming the fight against several different types of cancer.

Innate said he would be paid a base salary of 470,000 euros ($490,000). He will also get free shares in the company and be eligible for pay and share bonuses, if certain targets were met.

Shares in Innate were 4 percent higher by 1230 GMT while AstraZeneca slipped 1.4 percent.

By Ben Hirschler

Source: Reuters

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach